Medicines to Outmatch Disease
Nurix (nurixtx.com) scores 73 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 33rd percentile of 14032 Healthcare brands.
Nurix Therapeutics is a biopharmaceutical company headquartered in San Francisco, United States, founded in 2012. The company develops degrader-based medicines that utilize the cell's natural protein degradation machinery to eliminate disease-causing proteins. Nurix positions itself as a pioneer in targeted protein degradation, aiming to establish this approach as a new standard of patient care. Its work targets diseases where traditional therapies are insufficient, serving patients, healthcare providers, and biopharmaceutical partners.
| Brand Name | Nurix |
|---|---|
| Domain | nurixtx.com |
| Industry | Healthcare |
| Founded | 2012 |
| Headquarters | San Francisco, United States |
| Main Competitors | Arvinas (80/100), Kymera Therapeutics (76/100), C4 Therapeutics (73/100), Monte Rosa Therapeutics (76/100), Foghorn Therapeutics (55/100) |
Moz Domain Authority 37/100 vs category average 41 / leader 97 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #1,198,666 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Discover Nurix Therapeutic" (Meta description too short (3 words). OG description present but brief) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, + Microdata, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), Facebook, Instagram; no detected presence on LinkedIn, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Nurix?", Claude could identify the brand as of October 2026. Nurix Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule therapies that modulate protein levels in the body, particularly through targeted protein degradation, to treat cancer and other diseases. Best known for Pioneering targeted protein degradation drug discovery platform, including partnerships with companies like Gilead and Sanofi.
When asked "Best brands similar to Nurix?", Claude would recommend Nurix as of October 2026. It's a well known name in the targeted protein degradation space within biotech, so I'd mention it if discussing innovative cancer drug discovery companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Nurix's main competitors in Healthcare: Arvinas (80/100), Kymera Therapeutics (76/100), C4 Therapeutics (73/100), Monte Rosa Therapeutics (76/100), Foghorn Therapeutics (55/100).
Sources: Brand Analyzer scan
Nurix has limited AI-search visibility, scoring 31/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 31, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Nurix official site
Nurix was founded in 2012. Nurix operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Nurix scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Nurix official site
Nurix Therapeutics is a biopharmaceutical company based in San Francisco, United States, founded in 2012. It focuses on developing degrader-based medicines that use the cell's natural protein degradation machinery to target and eliminate disease-causing proteins.
Sources: Nurix official site
Nurix designs degrader-based medicines that harness the cell's natural protein degradation machinery to eliminate disease-causing proteins. The company works to establish targeted protein degradation as a therapeutic approach for diseases where conventional treatments are inadequate, serving patients, healthcare providers, and biopharmaceutical partners.
Sources: Nurix official site
Nurix can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Nurix official site
Nurix offers degrader-based medicines developed using targeted protein degradation technology. These are designed to harness the cell's natural protein degradation machinery to eliminate disease-causing proteins, representing a therapeutic platform rather than a single product line.
Sources: Nurix official site
Nurix is known for its pioneering work in targeted protein degradation, a therapeutic approach that uses the cell's own protein degradation pathways to remove disease-causing proteins, positioning the company at the forefront of this emerging field in medicine.
Sources: Nurix official site
Nurix's work is intended for patients, healthcare providers, and biopharmaceutical partners who are seeking innovative treatments for diseases where traditional therapies have proven insufficient.
Sources: Nurix official site
Nurix scores 31/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Nurix has a weak AI-visibility profile at 31/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,198,666 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 37/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Nurix from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Nurix: VidaVital Medical (73/100), Nuleaf Naturals (73/100), Nutrasource (73/100), Nutreov (73/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.